A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics
- Acronyms SoMOSA
- Sponsors Novartis
- 11 Apr 2017 Status changed from active, no longer recruiting to recruiting.
- 03 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2015 New trial record